selected publications
-
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
JAMA oncology.
2020
Academic Article
GET IT
Times cited: 106 -
COVID-19 in patients with lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020
Academic Article
GET IT
Times cited: 196 -
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Cancer discovery.
2020
Academic Article
GET IT
Times cited: 172 -
The Evolving Landscape of Resistance to Osimertinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2020
Editorial Article
GET IT
Times cited: 12 -
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2019
Academic Article
GET IT
Times cited: 247 -
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
Journal of the National Cancer Institute.
2019
Academic Article
GET IT
Times cited: 98 -
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.
Annals of oncology : official journal of the European Society for Medical Oncology.
2019
Academic Article
GET IT
Times cited: 287 -
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.
Cold Spring Harbor molecular case studies.
2019
Academic Article
GET IT
Times cited: 23 -
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.
Proceedings of the National Academy of Sciences of the United States of America.
2018
Academic Article
GET IT
Times cited: 42 -
Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
2018
Information Resource
GET IT
Times cited: 9 -
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 204 -
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 320 -
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 20 -
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Cancer.
2017
Academic Article
GET IT
Times cited: 28 -
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.
Lung cancer (Amsterdam, Netherlands).
2017
Academic Article
GET IT
Times cited: 7 -
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
Lung cancer (Amsterdam, Netherlands).
2017
Academic Article
GET IT
Times cited: 43 -
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 490 -
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017
Academic Article
GET IT
Times cited: 39 -
Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.
PloS one.
2016
Academic Article
GET IT
Times cited: 17 -
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015
Academic Article
GET IT
Times cited: 319 -
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Cancer.
2015
Academic Article
GET IT
Times cited: 184 -
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015
Academic Article
GET IT
Times cited: 74 -
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Cancer discovery.
2015
Academic Article
GET IT
Times cited: 490 -
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 90 -
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Cancer.
2015
Academic Article
GET IT
Times cited: 14 -
Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2015
Academic Article
GET IT
Times cited: 112 -
Small-cell lung cancers in patients who never smoked cigarettes.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2014
Academic Article
GET IT
Times cited: 110 -
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
International journal of radiation oncology, biology, physics.
2014
Academic Article
GET IT
Times cited: 85 -
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.
Annals of oncology : official journal of the European Society for Medical Oncology.
2014
Academic Article
GET IT
Times cited: 176 -
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.
Nature reviews. Clinical oncology.
2013
Article
GET IT
Times cited: 80 -
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013
Academic Article
GET IT
Times cited: 2085 -
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2013
Academic Article
GET IT
Times cited: 290 -
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.
Journal of the National Comprehensive Cancer Network : JNCCN.
2013
Academic Article
GET IT
Times cited: 68 - Who should receive EGFR tyrosine-kinase inhibitors?. The Lancet. Oncology. 2012 Article GET IT